Research Groups and R&D Platforms: In Vitro Diagnostics
R&D Platform:
Cancer Centre of the Turku University Hospital
The Tyks Cancer Centre guarantees high-quality cancer treatment and research in the hospital districts of Southwest Finland, Satakunta and Vaasa.
The Tyks Cancer Centre works to unify treatment practices and treatment quality, and to see to it that patients get access to treatment according to unified criteria in a timely manner in the western coastal area of Finland. This puts the patients with cancer at the right place at the right time, regardless of where they live.
The Tyks Cancer Centre is a part of the Cancer Center Finland (FICAN) – a national enterprise under construction to coordinate cancer treatment, research and education in the whole of Finland.
Breast cancer, Cancer, Clinical development, Colorectal cancer, Diagnostics, In Vitro Diagnostics, In Vivo Diagnostics, Lung cancer, Melanoma, Ovarian cancer, Prostate cancer, R&D Platforms, Squamous cell carcinoma
R&D Platform:
Turku Metabolomics Centre
The Turku Metabolomics Centre (TMC) was established in the Fall of 2017, and currently comprises four analytical laboratories on the University of Turku and Åbo Academy campuses, with the primary focus on biomedical and clinical applications. TMC covers a broad range of analytical methods, useful for discovery studies, hypothesis-driven targeted studies as well as clinical applications in Good Laboratory Practice (GLP) setting. The methods include:
1. Targeted quantitative analyses by mass spectrometry (MS) of specific groups of metabolites, e.g. bile acids, endocannabinoids, amino acids, eicosanoids.
2. Global profiling of molecular lipids (lipidomics) and polar metabolites.
3. Diagnostic, drug metabolism and pharmacokinetic applications in Good Laboratory Practice (GLP) setting.
4. Tissue metabolomics by Nuclear Magnetic Resonance (NMR).
5. How dietary intake affects blood metabolism.
TMC infrastructure currently includes 7 MS instruments (2 x UHPLC-QTRAP/QqQ-MS, 2 x UHPLC-QqQ-MS, 1 x GC-QqQ-MS, 2 x GC-QMS) and 2 NMR instruments (1 x 600 MHz and 1 x 400 MHz). The 400 MHz spectrometer is equipped with a high resolution magic angle spinning probe for the detection of metabolites in tissue and cell samples without the need for extensive sample preparation. The 600MHz instrument is equipped with a cooled sample handling robot with space for 300 samples allowing high throughput liquid NMR studies. Two new MS instruments also being purchased this year.
Basic research, Bioinformatics, Diagnostics, In Vitro Diagnostics, Machine learning, Metabolomics, NMR, Pattern recognition, R&D Platforms, Systems Biology, Target discovery
Research Group:
Cytoskeletal and survival signaling
John Eriksson
john.eriksson[at]abo.fi
Turku Bioscience Centre &
Cell Biology, Faculty of Science and Engineering,
Åbo Akademi University
Cytoskeletal and survival signaling
Atomic-force microscopy, Basic research, Biochemistry, Cancer, Diabetes, Diagnostics, Electron microscopy, High throughput imaging, Imaging, In Vitro Diagnostics, Metabolic diseases, Molecular Biology, Molecular Cell Biology, Nanoparticles, Natural Compounds, Natural products, Physiology, Proteomics, Receptor, Signaling, Super-resolution imaging, Target discovery
Research Group:
Novel multitargeting therapies for neurodegenerative diseases
Timo Myöhänen
timo.myohanen[at]utu.fi
Institute of Biomedicine,
University of Turku
PREP in Neurodegenerative Disorders (Helsinki-group page)
Ageing-related diseases, Assay development, Basic research, Biomedicine, Diagnostics, Disease models, Drug target, Imaging software, In Vitro Diagnostics, In Vivo Diagnostics, MALS or SEC-MALS, Medicinal chemistry, Molecular Biology, Molecular modelling, Neurological disorders, PET, Pharmacology, Signaling, Target discovery
Research Group:
Recombinant antibodies and other bioaffinity molecules
Urpo Lamminmäki
urplammi[at]utu.fi
Department of Life Technologies,
University of Turku
Antibodies, Assay development, Basic research, Biomarker, Biotechnology, Cancer, Combinatorial chemistry, Diagnostics, Drug target, Fluorescence spectroscopy, Hit to lead, In Vitro Diagnostics, Infection, Lead optimization, Metabolic diseases, Molecular Biology, Molecular modelling, Nanoparticles, Next-generation sequencing, Ovarian cancer, Point of care, Prostate cancer, Screening, Synthetic Biology, Target discovery
